drugset / Trial / NCT05371379
Multiple Ascending Dose Study of CM338 in Healthy Volunteers
RandomizedSequentialQuadruple-blindTreatment
Summary
This study was a multi-center, randomized, double blind, placebo-controlled, single-dose, dose escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM338 with multiple dosing in healthy subjects.
Timeline
- Start
- 2022-05-24
- Primary completion
- 2022-11-04
- Completion
- 2022-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM338 | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | CM338 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | CM338 | Monoclonal antibody | 300 mg | Subcutaneous |
Indications
No indication recorded.